The method of separation of placenta in cows

 

The invention relates to agriculture and veterinary medicine. The method includes the introduction of a sick cow 3-6 h after calving pararectal in the region hypogastric nerve plexus oil-water emulsion at a dose of 9,82-14,03 g containing medicinal substances in the following ratio, wt.%: sinistral, 2% oil solution 17,82-18,3, novocaine 17,82-18,3, sunflower oil or 49.9-51,0, phenol and 0.2 to 0.21, the rest distilled water. The method is highly efficient for retention of placenta and treatment of endometritis in cows. table 1.

The invention relates to agriculture, veterinary medicine, particularly to a method of separating the rear of the placenta of the cow after administration of a drug.

Due to anatomical and physiological characteristics of the relationship of the villi of cotyledons children's place and crypts of carbuncles of the uterus [1] and functional disorders of metabolic processes in the organism of pregnant cows in the winter-spring period the stabling (insufficient intake of vitamins, minerals and other substances, physical inactivity, permanent location in a cold space, the air, which contains significant amounts of carbon dioxide, hydrogen sulfide representing the full-nutrient substrate for the existing and rapidly growing microorganisms. They are in the process of their life produce toxins that inhibit the activity of neuro-humoral system, protective adaptations of the organism, contributing to atony of the uterus.

There is a method of separation of placenta after introduction into the body of the patient animal sinistral, oxytocin and other drugs [4].

Descriptions of how the combined use of sinistral with novocaine and vegetable oils, us patent and periodical literature was not found.

The purpose of the invention is the enhancement of therapeutic effectiveness in retention of placenta and treatment of endometritis after ingestion of the drug, improvement, convenience and safety of veterinary specialists.

This objective is achieved in that a sick cow in 3-6 hours after calving pararectal in the region hypogastric nerve plexus is injected oil-in-water emulsion containing medicinal substances with the following ratio of components (see table).

Injection technique with oil-in-water emulsion: - right or left podhvativaiu hole with observance of aseptic and antiseptic needle of the syringe parallel to the rectum and to injectable drug hit the area of pitcrew regenum factor increases blood flow, stimulates proliferative processes and involution of the uterus, helps eliminate common disorders, stimulates the nonspecific resistance of the organism and its resistance to microbial toxins, promotes nitrogen metabolism, improves nutrient utilization [2, 3]; - novocaine has a local anesthetic effect, when the absorption in the blood reduces the formation of acetylcholine, which reduces the excitability of the peripheral chainreaction systems, has a blocking effect on the autonomic ganglia, reduces spasm of smooth muscles of the uterus, reduces the excitability of the heart muscle and motor areas of the cerebral cortex [3]; - sunflower oil consists mainly of glycerides of oleic and linoleic acids, acts as a filler of the drug and detonator absorbability and action of drugs [3]; - phenol has a strong detrimental effect on the vegetative forms of microorganisms, is used for conservation of the drug [3]; - distilled water is the solvent of novocaine.

The industrial tests of the action of the drug for several years received quite promising results, we believe that predlagemogo application in practice facilitate the work will increase the culture and safety of veterinary specialists.

Literature 1. Akaev A. I. Anatomy of domestic animals. M., 1975, S. 337, 509.

2. Zhyrbenko A. M. Hormones and productivity of animals. Kiev, 1987, S. 36, 37.

3. Mashkovsky M. D. Medicines. M., 1987, 326 S., 584, 404.

4. Studentsov A. P., Shipilov C. S. and other Veterinary obstetrics and gynecology. M., 1980, S. 210-215.

Claims

The method of separation of placenta in cows, including the introduction of a drug, characterized in that the sick cow 3-6 h after calving pararectal in the region hypogastric nerve plexus is administered at a dose of 9,82-14,03 g drug of the following composition, wt. %: Sinestral, 2% oil solution - 17,82-18,3
Novocaine - 17,82-18,3
Sunflower oil - a 49.9-51,0
Phenol is 0.2 to 0.21
Distilled water - the Rest

 

Same patents:

The invention relates to medicine

The invention relates to veterinary pharmacology, obstetrics and gynecology

The invention relates to medicine, in particular to obstetrics
The invention relates to medicine, in particular to obstetrics and gynecology, and can be used for labor induction and termination of pregnancy for various indications

The invention relates to new inhibitors asteroidsurfaces used to treat astronuwiki tumors, in particular breast cancer

The invention relates to veterinary

The invention relates to medicine and relates to pharmaceutical compositions comprising a compound of formula I, having steroidsbritney activity

The invention relates to medicine

The invention relates to medicine, namely to the system of drug delivery, preferably in the form of a ring, suitable for vaginal administration, for simultaneous release progestogennoe steroid compounds and estrogenic steroid compounds in a fixed physical relationship for an extended period of time

The invention relates to dosage forms and method of treatment of disorders of erectile function in male patients

The invention relates to the field of pharmaceutical industry and relates to a method of obtaining a pharmaceutical composition
The invention relates to medicine, in particular to neurosurgery, and can be used to prevent rough scar adhesions between the membranes of the brain
The invention relates to medicine, in particular to the gynecologist, and for the treatment of chronic anovulation, including

FIELD: medicine, immunology.

SUBSTANCE: invention proposes an agent enhancing the immunogenic properties of tetanus anatoxin (adjuvant). Invention proposes the vegetable triterpenic compound miliacin as an agent enhancing immunogenic properties of tetanus anatoxin. Agent enhances the immune response value in its applying as a vaccine preparation of tetanus anatoxin. The agent miliacin elicits its stimulating effect for both the first and repeated administration of vaccine that allows suggesting its possible applying for prophylactic vaccinations with tetanus anatoxin. Taking into account the high tolerance of miliacin in the broad range of its doses it is suggested its practical applying as an agent promoting to the enhanced formation of vaccinal immunity in prophylactic vaccinations with tetanus anatoxin.

EFFECT: valuable medicinal properties of agent.

6 tbl

FIELD: organic chemistry, steroids, pharmacy.

SUBSTANCE: invention describes unsaturated 14,15-cyclopropanoandrostanes of the general formula (I):

wherein R1 means hydrogen atom (H), hydroxy-group (OH); R2 means hydroxy-group (OH), hydrogen atom (H); R3 means hydrogen atom (H), (C1-C10)-alkyl at α- or β-position; R4 means halogen atom (F, Cl, Br) or pseudohalogen group (azide, rhodanide), hydroxy-group (OH), perfluoroalkyl; R5 means (C1-C4)-alkyl; if double bond is at 1,2-position then R4 can mean hydrogen atom (H). Also, invention relates to a method for preparing these compounds and pharmaceutical compositions containing these compounds. Compounds of the formula (I) are compounds eliciting gestagenic and/or androgenic effect.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

11 cl, 1 tbl, 9 ex

FIELD: medicine, gynecology.

SUBSTANCE: the present innovation deals with carrying out hormone-substitution therapy in women during menopause period or in sterilized women. For this purpose the above-mentioned therapy consists of the phase of relative dominant estrogen activity including three daytime dosages of a substance inducing estrogen activity being equivalent to approximately to 1 mg 17beta-estradiol daily, and the phase of relative dominant progestogen activity including combination of a substance inducing estrogen activity being equivalent to approximately 1 mg 17beta-estradiol daily and a substance that demonstrates progestogen activity being equivalent to approximately 90 mcg norgestimate daily. To fulfill such a therapy a pharmaceutical preparation is, also, suggested and a set of mentioned preparations. The innovation provides maximal weakening the symptoms of the disease, in particular, congestions along the safety of application due to decreased risk of known complications of estrogen therapy.

EFFECT: higher efficiency of therapy.

31 cl, 1 dwg, 1 ex, 2 tbl

FIELD: organic chemistry, steroids, pharmacy.

SUBSTANCE: invention relates to a new type of selective estrogens comprising steroid structure of the general formula (I) with nonaromatic ring A and free of bound hydroxyl group at carbon atom 3 wherein R1 means hydrogen atom (H), (C1-C3)-alkyl or (C2-C3)-acyl; R2 means hydrogen atom (H), α-(C1-C4)-alkyl, α-(C2-C4)-alkenyl or α-(C2-C4)-alkynyl; R3 means hydrogen atom (H) or (C1-C4)-alkyl at position 16 of steroid structure; R4 means ethynyl; R5 means hydrogen atom (H), (C1-C3)-alkyl or (C2-C3)-acyl; R6 means (C1-C5)-alkyl, (C2-C5)-alkenyl, (C2-C5)-alkynyl being each of that is substituted optionally with chlorine or fluorine atom; dotted line means the optional double bond. Compounds of the formula (I) elicit the selective affinity to ERα-receptors.

EFFECT: valuable properties of compounds and composition.

4 cl, 3 sch, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.

EFFECT: higher efficiency of prophylaxis.

1 cl, 1 ex, 4 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition as a capsule for oral administration that comprises testosterone undecanoate as an active component dissolved in pharmaceutically acceptable liquid carrier wherein liquid carrier involves at least 50 wt.-% of castor oil. Using castor oil as a liquid carrier in combination with testosterone undecanoate as androgen provides preparing a solution that can contain about 200-250 mg of testosterone undecanoate/ml that represents the new achievement for testosterone solution for oral administration. Solution can contain lipophilic surface-active substance, such as lauryl glycol also. The composition shows good absorption in human body and elicits higher activity as compared with the known composition of undecanoate.

EFFECT: improved and valuable properties of composition.

7 cl, 1 ex

Up!